flumethasone dipropionate

Flumethasone dipropionate (also referred to as dipropionate flumethasone) is a topical corticosteroid small molecule drug. It is described in clinical trial contexts as a synthetic glucocorticoid that targets the glucocorticoid receptor (GR) to exert anti-inflammatory, antipruritic, and vasoconstrictive effects. It is being developed by Zenith Technology Corporation Limited for the treatment of inflammatory skin conditions, specifically eczema and psoriasis, and has been studied in pivotal in vivo bioequivalence trials as a topical cream formulation. Note that the chemical name provided in some sources for this drug (9-fluoro-11β-hydroxy-16β-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate) actually corresponds to betamethasone dipropionate, suggesting a nomenclature error in those records.

Other names

dipropionate flumethasone